Changing common sense:Anti-platelet/coagulation therapy against cirrhosis |
| |
Authors: | Yoshihiro Ikura Tatsuya Osuga |
| |
Institution: | Yoshihiro Ikura, Department of Pathology, Takatsuki General Hospital, Takatsuki 569-1192, JapanTatsuya Osuga, Department of Gastroenterology, Takatsuki General Hospital, Takatsuki 569-1192, Japan |
| |
Abstract: | Until recently,anti-platelet/coagulation therapy had not been recommended for patients with cirrhosis.Although venous thrombosis is one of the representative complications of cirrhosis and ischemic disorders associated with atherosclerosis are not infrequent in cirrhotic patients,many clinicians have tended to hesitate to introduce anti-platelet/coagulation therapy to their patients.Undoubtedly,this is due to the increased risk of hemorrhagic diathesis in cirrhotic patients.However,accumulating evidence has revealed the benefits of anti-platelet/coagulation therapy for cirrhotic patients.In addition to the safety of the therapy carried out against cardiovascular diseases in cirrhotic patients,some clinical data have indicated its preventive effect on venous thrombosis.Moreover,the efficacy of antiplatelet/coagulation therapy against cirrhosis itself has been demonstrated both clinically and experimentally.The conceptual basis for application of anti-platelet/coagulation therapy against cirrhosis was constructed through two pathologic studies on intrahepatic thrombosis in cirrhotic livers.It may be better to use thrombopoietinreceptor agonists,which have been tested as a treatment for cirrhosis-related thrombocytopenia,in combination with anti-platelet drugs to reduce the risk of venous thrombosis.During the last decade,the World Journal of Gastroenterology,a sister journal of World Journal of Hepatology,has been one of the main platforms of active discussion of this theme. |
| |
Keywords: | Anti-platelet/coagulation therapy Cirrhosis Hemorrhagic diathesis Thrombosis Thrombocytopenia |
本文献已被 CNKI 等数据库收录! |
| 点击此处可从《World journal of hepatology》浏览原始摘要信息 |
|